Key result
Dual-acting angiotensin-receptor neprilysin inhibitors (ARNi) are under scientific scrutiny for the treatment of hypertension and heart failure.
Design
Review
Authors
Loading...
ARNi merit continued scrutiny in hypertension and HF; leaves open clinical adoption pending dedicated trials.
Dual-acting angiotensin-receptor neprilysin inhibitors (ARNi) represent a promising therapeutic strategy for hypertension and heart failure by simultaneously blocking the renin-angiotensin system and augmenting the natriuretic peptide system.
Lueder et al. (2013) conducted a review in Heart failure and hypertension. Angiotensin-receptor neprilysin inhibitors (ARNi) was evaluated. Dual-acting angiotensin-receptor neprilysin inhibitors (ARNi) are under scientific scrutiny for the treatment of hypertension and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: